Synonym
MDL-72974A; MDL72974A; MDL 72974A; MDL-72,974A; MDL72,974A; MDL 729,74A; Mofegiline hydrochloride
IUPAC/Chemical Name
(E)-2-(Fluoromethylene)-4-(p-fluorophenyl)butylamine hydrochloride
InChi Key
QUCNNQHLIHGBIA-HCUGZAAXSA-N
InChi Code
InChI=1S/C11H13F2N.ClH/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9;/h3-7H,1-2,8,14H2;1H/b10-7+;
SMILES Code
NC/C(CCC1=CC=C(F)C=C1)=C/F.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
119386-96-8 (Mofegiline)
120635-25-8 (Mofegiline hydrochloride)
Biological target:
Mofegiline hydrochloride (MDL72974A) is an orally active and selective enzyme-activated irreversible inhibitor of MAO-B, with marked selectivity on the MAO-B over MAO-A with IC50s of 3.6 nM (MAO-B) and 680 nM (MAO-A).
In vitro activity:
MDL 72,974, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine, was designed to be a selective inhibitor of monoamine oxidase type B (MAO-B). In vitro, the compound inhibits rat brain mitochondrial MAO in a concentration and time-dependent fashion and shows marked selectivity for the B form (IC50 = 680 and 3.6 nM for MAO-A and MAO-B, respectively).
Reference: J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54. https://pubmed.ncbi.nlm.nih.gov/2597310/
In vivo activity:
This study has recently observed a reduction in the density of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra of mice treated with MDL72974. Results demonstrate a significant increase in superoxide dismutase (SOD) activity, a key antioxidant, in the striatum and cerebellum of MDL72974-treated mice, presumably in response to free radical production
Reference: Synapse. 1998 Mar;28(3):208-11. https://pubmed.ncbi.nlm.nih.gov/9488505/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
110.0 |
470.72 |
| Water |
25.0 |
106.98 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
233.69
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Thiffault C, Quirion R, Poirier J. The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):127-36. doi: 10.1016/s0169-328x(97)00135-6. PMID: 9387872.
2. Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54. doi: 10.1007/BF02263478. PMID: 2597310.
3. Thiffault C, Quirion R, Poirier J. Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain. Synapse. 1998 Mar;28(3):208-11. doi: 10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID: 9488505.
4. Yu PH, Zuo DM. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem Pharmacol. 1992 Jan 22;43(2):307-12. PMID: 1739419.
In vitro protocol:
1. Thiffault C, Quirion R, Poirier J. The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):127-36. doi: 10.1016/s0169-328x(97)00135-6. PMID: 9387872.
2. Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54. doi: 10.1007/BF02263478. PMID: 2597310.
In vivo protocol:
1. Thiffault C, Quirion R, Poirier J. Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain. Synapse. 1998 Mar;28(3):208-11. doi: 10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID: 9488505.
2. Yu PH, Zuo DM. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem Pharmacol. 1992 Jan 22;43(2):307-12. PMID: 1739419.
1: Milczek EM, Bonivento D, Binda C, Mattevi A, McDonald IA, Edmondson DE.
Structural and mechanistic studies of mofegiline inhibition of recombinant human
monoamine oxidase B. J Med Chem. 2008 Dec 25;51(24):8019-26. doi:
10.1021/jm8011867. PubMed PMID: 19053775; PubMed Central PMCID: PMC2706497.
2: Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S. Pharmacokinetics and
pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during
a phase I dose tolerance trial. Clin Pharmacol Ther. 1995 Sep;58(3):342-53.
PubMed PMID: 7554709.
3: Huebert ND, Dulery BD, Schoun J, Schwach V, Hinze C, Haegele KD. Kinetics and
metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline. Clin
Pharmacol Ther. 1994 Nov;56(5):537-42. PubMed PMID: 7955818.
4: Dow J, Piriou F, Wolf E, Dulery BD, Haegele KD. Novel carbamate metabolites of
mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Drug Metab Dispos. 1994 Sep-Oct;22(5):738-49. PubMed PMID: 7835226.
